Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Press Releases Ypsomed Group

Burgdorf / Indianapolis – Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.

Press Releases Ypsomed Group

Burgdorf / Mainz / Basel – Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment.

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased sales by 4.6% or CHF 8.7 million in the first six months of 2020/21 compared to the previous year, and generated an operating profit (EBIT) of CHF 8.3 million. The company continued on its growth course in a challenging environment, driving forward all strategic initiatives and creating 102 new jobs at the same time.

Notizie Ypsomed Italia

Burgdorf/San Diego – Ypsomed (SWX:YPSN) e DexCom Inc. (NASDAQ:DXCM), leader mondiale di sistemi di monitoraggio in continuo della glicemia (CGM), annunciano la loro partnership per sviluppare un sistema ibrido ad ansa chiusa. Questa collaborazione è una pietra miliare importante per il successivo sviluppo di una terapia del diabete individualizzata. Come primo passo, i dati del CGM Dexcom saranno integrati nella mylife App di Ypsomed.

Notizie Ypsomed Italia

Varese - Ypsomed Italia, sensibile alle problematiche sociali e responsabilmente attiva, in questo delicato momento, nella lotta alla diffusione dell’epidemia da COVID-19, ha deciso di ridurre o sospendere le attività normalmente svolte a contatto con il pubblico e con gli operatori sanitari, presso le strutture sanitarie ambulatoriali e/o di degenza. Per lo stesso motivo precauzionale abbiamo sospeso tutti i meeting e le partecipazioni a convegni e congressi, fino a data da destinarsi.